TriClip Abbott has received the CE mark for its TriClip transcatheter tricuspid valve repair system and is now approved for use in Europe and other countries that recognise the CE mark. It can, therefore, be used as a non-surgical treatment for people with a leaky tricuspid valve. A press release reports that [...]
TriClip New data indicate that a novel transcatheter system for tricuspid valve repair (TriClip, Abbott) was safe and associated with strong clinical improvement at six-months—including a reduction in tricuspid regurgitation and improvement in quality of life—in patients with severe tricuspid regurgitation. The findings were presented at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) [...]
Abbott has announced its TRILUMINATE Pivotal trial to evaluate the safety and effectiveness of the TriClip transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation. This is the first pivotal Investigational Device Exemption (IDE) trial in the USA to evaluate a catheter-based, non-surgical treatment for patients with severe tricuspid regurgitation. The [...]